While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly ( LLY -0.50%) has emerged ...

Eli Lilly’s Global CEO David Ricks revealed that the pharma giant might manufacture its weight-loss blockbuster, Mounjaro, in ...

Eli Lilly's MounjaroNow, Eli Lilly, the largest pharmaceutical company in the world in terms of market capitalisation, has ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India, marking its entry into a rapidly growing market.

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, ...

Cristina Arias / Cover / Getty Images Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly ... and Wegovy and Lilly's Mounjaro and Zepbound.

In that time, Eli Lilly has seen explosive growth, largely due to its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound. Mounjaro brought in $11.5 billion in sales in 2024 ...

(Reuters) - Eli Lilly plans to launch its blockbuster diabetes ... In February last year, CEO David Ricks told Reuters that Lilly expects to launch Mounjaro in India as early as 2025. Mounjaro, ...

March 10 (Reuters) - Eli Lilly (LLY.N), opens new tab ... In February last year, CEO David Ricks told Reuters that Lilly expects to launch Mounjaro in India as early as 2025.

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico in 2025, Chief Financial Officer Lucas Montarce said on Monday.